Trial · NCT01167881
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change in Body Weight From Baseline After 104 Weeks of Treatment. | Empaglifozin 25 mg | -3.11 | Standard Error 0.13 | kilograms | |
| The Change in Body Weight From Baseline After 104 Weeks of Treatment. | Glimepiride | 1.33 | Standard Error 0.13 | kilograms | |
| The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment. | Empaglifozin 25 mg | -0.66 | Standard Error 0.03 | percentage of HbA1c | |
| The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment. | Glimepiride | -0.55 | Standard Error 0.03 | percentage of HbA1c | |
| The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment. | Empaglifozin 25 mg | 19 | participants | ||
| The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment. | Glimepiride | 189 | participants | ||
| The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment. | Empaglifozin 25 mg | -3.1 | Standard Error 0.5 | mmHg | |
| The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment. | Glimepiride | 2.5 | Standard Error 0.5 | mmHg | |
| The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment. | Empaglifozin 25 mg | -1.8 | Standard Error 0.3 | mmHg | |
| The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment. | Glimepiride | 0.9 | Standard Error 0.3 | mmHg | |
| The Change From Baseline in HbA1c After 52 Weeks of Treatment. | Empaglifozin 25 mg | -0.73 | Standard Error 0.03 | percentage of HbA1c | |
| The Change From Baseline in HbA1c After 52 Weeks of Treatment. | Glimepiride | -0.66 | Standard Error 0.03 | percentage of HbA1c | |
| The Change in Body Weight From Baseline After 52 Weeks of Treatment. | Empaglifozin 25 mg | -3.21 | Standard Error 0.12 | kilograms | |
| The Change in Body Weight From Baseline After 52 Weeks of Treatment. | Glimepiride | 1.59 | Standard Error 0.11 | kilograms | |
| The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment. | Empaglifozin 25 mg | 12 | participants | ||
| The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment. | Glimepiride | 159 | participants | ||
| The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment. | Empaglifozin 25 mg | -3.6 | Standard Error 0.5 | mmHg | |
| The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment. | Glimepiride | 2.2 | Standard Error 0.5 | mmHg | |
| The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment. | Empaglifozin 25 mg | -1.9 | Standard Error 0.3 | mmHg | |
| The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment. | Glimepiride | 1.0 | Standard Error 0.3 | mmHg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01167881/results